Willamette Valley Cancer Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Eugene OR United States

Organization Overview

First Clinical Trial
2011
NCT00455052
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Willamette Valley Cancer Institute and Research Center | Willamette Valley Clinical Studies

Active Ingredients

Drugs in Phase 3 Trials (2)

ibrutinib (imbruvica) (2 trials)

ublituximab (Briumvi) (2 trials)

Drugs in Phase 2 Trials (2)

sitagliptin (januvia) (1 trial)

tw1025 (1 trial)

Drugs in Phase 1 Trials (1)

xmt-1001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fatigue (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lung Neoplasms (Phase 1)

Lymphoma, Mantle-Cell (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5